0NF7.L - PCAS SA
| Chiusura precedente | 0,00 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,95 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation
Ecully, May 25th, 2023 PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation PCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, has made the decision to sell PCAS Canada Inc., the Canadian subsidiary of PCAS Group, to DIC Corporation, a Japanese chemicals group with a presence in more than 60 countries. An enterprise value of 88.2 million euros has been agreed for PCAS
- GlobeNewswire
PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.
Ecully, May 2nd, 2023 PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc. PCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, announces the receipt of an offer from DIC Corporation, a Japanese chemical corporate group with a presence in more than 60 countries, for the acquisition of PCAS
- GlobeNewswire
PCAS: RELEASE OF THE 2022 UNIVERSAL REGISTRATION DOCUMENT (URD)
RELEASE OF THE 2022 UNIVERSAL REGISTRATION DOCUMENT (URD) Ecully, April 28, 2023 The PCAS Universal Registration Document 2022, which includes the annual financial report, was filed with France's Financial Markets Authority, in ESEF format (European Single Electronic Format), on April 27, 2023, under number D.23-0356. This document contains: The 2022 annual financial reportThe Board of Directors' corporate governance report in accordance with Section L.225-37 of France's Commercial CodeThe statu
- GlobeNewswire
Pcas: NET SALES AS OF MARCH 31, 2023
Ecully, April 24, 2023 NET SALES AS OF MARCH 31, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of March 31, 2023. The PCAS Group has generated consolidated net sales of €66.2 million as of March 31, 2023, a 29.4% increase compared to the same period during the previous financial year (+28.3% at a constant exchange rate). In millions of euros
- GlobeNewswire
Pcas: 2022 annual results
Ecully, March 30, 2023 2022 ANNUAL RESULTS PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its 2022 Annual Results, following today's Board of Directors meeting. 2021 2022 in millions of euros Net sales 187.0 226.4 EBITDA (*) (**) -4.6 2.2 EBITDA margin -2.5% 1.0% Current operating income (*) -28.2 -27.7 Current operating income margin -15.1% -12.2% Other operating income and ex
- GlobeNewswire
PCAS: NET SALES AS OF DECEMBER 31, 2022
Ecully, February 7, 2023 NET SALES AS OF DECEMBER 31, 2022 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of December 31, 2022. The PCAS Group has generated consolidated net sales of €226.4 million as of December 31, 2022, a 21.1% increase compared to the same period during the previous financial year (+17.9% at a constant exchange rate). In millio
- GlobeNewswire
Press release of December 21, 2022
Ecully, December 21, 2022 The PCAS Board of Directors met on December 20, 2022. During this meeting, the Board of Directors focused on the difficulties encountered in the development of financial and commercial relations with a major client of the Group. PCAS is facing significant delays in the payment by this client of invoices corresponding to work carried out and delivered. Due to these unjustified late payments which correspond to very significant amounts and the impossibility as of today to
- GlobeNewswire
PCAS: appointment of a new Chairman
+ Ecully, November 28, 2022 APPOINTMENT OF A NEW CHAIRMAN At its meeting of November 28, 2022, the PCAS Board of Directors formally acknowledged the resignation of Mr. Philippe Clavel as Chief Executive Officer of PCAS. The Board of Directors thanked Mr. Philippe Clavel for his collaboration with PCAS Group. Consequently, the Board of Directors decided to appoint Mr. Jean-Louis Martin as Chief Executive Officer of PCAS. Mr. Jean-Louis Martin, currently Vice President Human Resources and Industri
- GlobeNewswire
PCAS: NET SALES AS OF SEPTEMBER 30, 2022
Ecully, November 3, 2022 NET SALES AS OF SEPTEMBER 30, 2022 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of September 30, 2022. The PCAS Group has generated consolidated net sales of €156.1 million as of September 30, 2022, a 9.6% increase compared to the same period during the previous financial year (+7.1% at constant exchange rates). In millio
- GlobeNewswire
1st HALF 2022 EARNINGS REPORT
Ecully, September 8, 2022 1st HALF 2022 EARNINGS REPORT PCAS (Euronext Paris: PCA), a specialist in the development and production of complex molecules for life sciences and innovative technologies, announces the publication of its consolidated earnings for the first half of 2022. 30 June 2021 30 June 2022 in millions of euros Net sales 106.3 109.8 EBITDA (*) 8.0 -0.5 EBITDA margin 7.5% -0.5% Current operating income (*) -2.6 -15.3 Other operating income and expenses -0.4 -14.7 Operating income
- GlobeNewswire
PCAS: NET SALES AS OF JUNE 30, 2022
Ecully, July 29, 2022 NET SALES AS OF JUNE 30, 2022 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of June 30, 2022. The PCAS Group has generated consolidated net sales of €109.8 million as of June 30, 2022, a 3.3% increase compared to the same period during the previous financial year (+1.4% at constant exchange rates). In millions of euros 2022 2